References
- SungH , FerlayJ , SiegelRLet al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2021).
- SwamiU , McFarlandTR , NussenzveigR , AgarwalN. Advanced prostate cancer: treatment advances and future directions. Trends Cancer6(8), 702–715 (2020).
- ChangSS. Overview of prostate-specific membrane antigen. Rev. Urol.6(Suppl. 10), S13–S18 (2004).
- PastorinoS , RiondatoM , UccelliLet al.Toward the discovery and development of psma targeted inhibitors for nuclear medicine applications. Curr. Radiopharm.13(1), 63–79 (2020).
- ScherHI , MorrisMJ , StadlerWMet al.Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol.34(12), 1402–1418 (2016).
- HofmanMS , LawrentschukN , FrancisRJet al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet395(10231), 1208–1216 (2020).
- FendlerWP , CalaisJ , EiberMet al.Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol.5(6), 856–863 (2019).
- HopeTA , GoodmanJZ , AllenIE , CalaisJ , FendlerWP , CarrollPR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J. Nucl. Med.60(6), 786–793 (2019).
- ZachoHD , RavnS , Afshar-OromiehA , FledeliusJ , EjlersenJA , PetersenLJ. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous (99m)Tc bone scintigraphy. EJNMMI Res.10(1), 31 (2020).
- YildirimÖA , GündoğanC , CanC , PoyrazK , ErdurE , KömekH. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann. Nucl. Med.35 (2021).
- AksuA , KarahanŞen NP , TunaEB , AslanG , ÇapaKaya G. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. Nucl. Med. Commun. (2021).
- AlbertsIL , SeideSE , MingelsCet al.Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. (2021).
- KyriakopoulosCE , ChenYH , CarducciMAet al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 chaarted trial. J. Clin. Oncol.36(11), 1080–1087 (2018).
- BuonerbaC , FerroM , DolcePet al.Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol.151, 1–9 (2020).
- DiLorenzo G , BuonerbaC. Oligometastatic prostate cancer: is it only a matter of perspective?Eur. Urol.75(5), 705–706 (2019).
- TriggianiL , MazzolaR , MagriniSMet al.Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J. Urol.37(12), 2631–2637 (2019).
- MoriK , MostafaeiH , PradereBet al.Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int. J. Clin. Oncol.25(11), 1892–1900 (2020).
- BuonerbaC , PondGR , SonpavdeGet al.Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Futur. Oncol.9(6), 889–897 (2013).
- DiLorenzo G , D'anielloC , BuonerbaCet al.Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs24(1), 84–89 (2013).
- HofmanMS , EmmettL , SandhuSet al.[177Lu]-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, Phase II trial. Lancet397(10276), 797–804 (2021).